1. Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006;19:CD003730PMID:
16625590.
2. Nagy J. Alcohol related changes in regulation of NMDA receptor functions. Curr Neuropharmacol 2008;6:39-54. PMID:
19305787.
3. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs 2008;22:761-786. PMID:
18698875.
4. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 2011;14:1127-1131. PMID:
21557878.
5. Zajaczkowski W, Frankiewicz T, Parsons CG, Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997;36:961-971. PMID:
9257940.
6. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-apartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999;38:735-767. PMID:
10465680.
7. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Ther 2004;26:615-630. PMID:
15220008.
9. Permoda-Osip A, Rybakowski J. Glutamatergic conception of mood disorders. Psychiatr Pol 2011;45:875-888. PMID:
22335130.
10. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161:171-174. PMID:
14702270.
11. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007;30:136-144. PMID:
17545748.
12. Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord 2012;136:163-166. PMID:
22030128.
13. Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord 2012;14:64-70. PMID:
22329473.
14. Keck PE Jr, Hsu HA, Papadakis K, Russo J Jr. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol 2009;32:199-204. PMID:
19620854.
15. Muhonen LH, Lönnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008;69:392-399. PMID:
18348597.
16. Muhonen LH, Lahti J, Sinclair D, Lönnqvist J, Alho H. Treatment of alcohol dependence in patients with co-morbid major depressive disorder -- predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy 2008;3:20PMID:
18834506.
17. Teng CT, Demetrio FN. Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder. Rev Bras Psiquiatr 2006;28:252-254. PMID:
17063225.
18. Munoz C, Yulan N, Achaval V, Appiani F, Carroll BT. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008;20:119-120. PMID:
18305307.
19. Obregon DF, Velasco RM, Wuerz TP, Catalano MC, Catalano G, Kahn D. Memantine and catatonia: a case report and literature review. J Psychiatr Pract 2011;17:292-299. PMID:
21775832.
20. Northoff G. What catatonia can tell us about "top-down modulation": a neuropsychiatric hypothesis. Behav Brain Sci 2002;25:555-577. PMID:
12958742.
21. Agarwal V, Tripathi A. Memantine in the management of a clinically challenging case of bipolar disorder. Indian J Psychiatry 2009;51:137-138. PMID:
19823634.
22. Martínez-Arán A, Vieta E, Reinares M, Colom F, Torrent C, Sánchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262-270. PMID:
14754775.
23. Osher Y, Dobron A, Belmaker RH, Bersudsky Y, Dwolatzky T. Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls. Psychother Psychosom 2011;80:298-303. PMID:
21646824.
24. Sani G, Serra G, Kotzalidis GD, Romano S, Tamorri SM, Manfredi G, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012;26:663-690. PMID:
22784018.
25. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 2010;12:348-349. PMID:
20565444.
26. Witkin JM, Li X. New approaches to the pharmacological management of major depressive disorder. Adv Pharmacol 2009;57:347-379. PMID:
20230766.
27. Enz R. Metabotropic glutamate receptors and interacting proteins: evolving drug targets. Curr Drug Targets 2012;13:145-156. PMID:
21777188.